Aspira Women's Health (AWH)

• Market cap: $12.8M
• 1 day: 0.65%
• 5 days: 4.35%
• 1 month: 5.48%
• 3 months: -4.48%
• 6 months: -54.17%
• Year to date: -81.58%
• 1 year: -70.61%
• 5 years: -98.76%
• 10 years: -99.86%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Employees: 64

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

3.43% more ownership

Funds ownership: 11.23% [Q2] → 14.66% (+3.43%) [Q3]

8% less funds holding

Funds holding: 26 [Q2] → 24 (-2) [Q3]

9% less capital invested

Capital invested by funds: $2.08M [Q2] → $1.9M (-$186K) [Q3]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6